These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29634072)

  • 21. Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity.
    Jain V; Sharma D; Prabhakar H; Dash HH
    Eur J Anaesthesiol; 2008 Feb; 25(2):166-7. PubMed ID: 18251038
    [No Abstract]   [Full Text] [Related]  

  • 22. Metformin: time to review its role and safety in chronic kidney disease.
    Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
    Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK.
    Li L; Jick S; Gopalakrishnan C; Heide-Jørgensen U; Nørrelund H; Sørensen HT; Christiansen CF; Ehrenstein V
    Diabet Med; 2017 Apr; 34(4):485-489. PubMed ID: 27504911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.
    van Berlo-van de Laar IR; Vermeij CG; Doorenbos CJ
    J Clin Pharm Ther; 2011 Jun; 36(3):376-82. PubMed ID: 21545617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contraindications can damage your health--is metformin a case in point?
    Holstein A; Stumvoll M
    Diabetologia; 2005 Dec; 48(12):2454-9. PubMed ID: 16283245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unleash metformin: reconsideration of the contraindication in patients with renal impairment.
    Lu WR; Defilippi J; Braun A
    Ann Pharmacother; 2013 Nov; 47(11):1488-97. PubMed ID: 24259604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
    Eppenga WL; Lalmohamed A; Geerts AF; Derijks HJ; Wensing M; Egberts A; De Smet PA; de Vries F
    Diabetes Care; 2014 Aug; 37(8):2218-24. PubMed ID: 24842984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin: effective and safe in renal disease?
    Herrington WG; Levy JB
    Int Urol Nephrol; 2008; 40(2):411-7. PubMed ID: 18368503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nephrotoxicity after the use of intravenous X-ray contrast media in a type 2 diabetic being treated with metformin].
    Bjarnason NH; Elung-Jensen T
    Ugeskr Laeger; 2006 May; 168(18):1772-3. PubMed ID: 16729932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Traditional contraindications to the use of metformin -- more harmful than beneficial?].
    Holstein A; Egberts EH
    Dtsch Med Wochenschr; 2006 Jan; 131(3):105-10. PubMed ID: 16418951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Four cases of lactic acidosis following metformin treatment].
    Frid A; Sterner G
    Lakartidningen; 2006 Sep 6-12; 103(36):2560-2. PubMed ID: 17007201
    [No Abstract]   [Full Text] [Related]  

  • 32. Metformin and contrast media.
    Thomsen HS; Morcos SK; Almén T; Aspelin P; Bellin MF; Clément O; Heinz-Peer G; Reimer P; Stacul F; van der Molen AJ; Webb JA
    Radiology; 2010 Aug; 256(2):672-3; author reply 673. PubMed ID: 20656850
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
    Richy FF; Sabidó-Espin M; Guedes S; Corvino FA; Gottwald-Hostalek U
    Diabetes Care; 2014 Aug; 37(8):2291-5. PubMed ID: 24879835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevention of lactic acidosis due to metformin intoxication in contrast media nephropathy].
    Landewé-Cleuren S; van Zwam WH; de Bruin TW; de Haan M
    Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1903-5. PubMed ID: 11045136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
    Radwan MA; Al Taweel ES; Al-Moghairi AM; Aloudah NM; Al Babtain MA; Al-Amri HS
    Ther Drug Monit; 2011 Dec; 33(6):742-9. PubMed ID: 22105592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin-induced lactic acidosis associated with acute renal failure.
    Safadi R; Dranitzki-Elhalel M; Popovtzer M; Ben-Yehuda A
    Am J Nephrol; 1996; 16(6):520-2. PubMed ID: 8955764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.
    Goergen SK; Rumbold G; Compton G; Harris C
    Radiology; 2010 Jan; 254(1):261-9. PubMed ID: 20032157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of metformin with intravenous iodinated contrast media and precautions.
    Shah MA; Niazi SG; Tahir IM; Shahid I; Parveen A; Sana S; Akhter N; Iftikhar N; Ashraf S; Siddique Z; Mushtaq Y; Khan M; Akram M
    Pak J Pharm Sci; 2019 Mar; 32(2 (Supplementary)):859-863. PubMed ID: 31103983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin in chronic kidney disease: time for a rethink.
    Heaf J
    Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Accumulation of Metformin-associated Lactic Acidosis].
    Rüegg T; Caduff B
    Dtsch Med Wochenschr; 2017 Mar; 142(6):428-431. PubMed ID: 28329904
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.